118 9 INTANgIblE ASSETS CoNTINuEd SIgNIFICANT ASSETS Carrying Remaining value amortisation Description $m period 1 Intangible assets arising from joint venture with Merck Product, marketing and distribution rights 262 5 and 9 years 1 Advance payment Product, marketing and distribution rights 528 10 years 1 Partial retirement nonrefundable deposit Product, marketing and distribution rights 1,656 Not amortised 1 Partial retirement Product, marketing and distribution rights 840 13-19 years 2 Intangible assets arising from the acquisition of CAT Product, marketing and distribution rights 398 7 and 12 years 2 Intangible assets arising from the acquisition of KuDOS Product, marketing and distribution rights 285 Not amortised 3 2 RSV franchise assets arising on acquisition of MedImmune Product, marketing and distribution rights 5,161 17-23 years 3 Intangible assets arising from the acquisition of MedImmune Licensing and contractual income 1,103 1-12 years 1 These assets are associated with the restructuring of the joint venture with Merck & Co. Inc. Further information can be found in Note 25.
2 Assets in development are not amortised but are tested annually for impairment.
3 An allocation of the cost of these assets to Therapy Area is given in Note 22.
10 oTHER INvESTmENTS 2008 2007 2006 $m $m $m Non-current investments Loans and receivables at fair value through profit or loss 37 Equity securities available for sale 156 182 82 156 182 119 Current investments Equity securities held for trading 50 31 26 Fixed deposits 54 60 559 Derivative financial instruments 284 86 72 388 177 657 Impairment charges of $25m in respect of available for sale securities are included in other operating income and expense in the income statement 2007: $18m: 2006: $nil.
11 INvENToRIES 2008 2007 2006 $m $m $m Raw materials and consumables 409 579 541 Inventories in process 631 806 778 Finished goods and goods for re-sale 596 734 931 1,636 2,119 2,250 Inventory write-offs in the year amounted to $51m 2007: $95m: 2006: $137m.
ASTRAZENECA ANNuAl REpoRT ANd FoRm 20-F INFoRmATIoN 2008
